{"id":792171,"date":"2024-12-03T16:36:12","date_gmt":"2024-12-03T21:36:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/"},"modified":"2024-12-03T16:36:12","modified_gmt":"2024-12-03T21:36:12","slug":"outlook-therapeutics-announces-executive-leadership-transition","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/","title":{"rendered":"Outlook Therapeutics\u00ae Announces Executive Leadership Transition"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ISELIN, N.J., Dec.  03, 2024  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ihXjcEoWxhQAg0vsph5i2W0UcUBuBqIjhjCCJmE_LLeZu5DkxYjGvVtULhCy_oyrAi2UNg3Bmci7IMZHybtb2CXkXlxzvhwuMVcPLskmd8YxCbG_n-7P1GaO_3pEY5rR\" rel=\"nofollow\" target=\"_blank\">Outlook Therapeutics, Inc.<\/a> (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA\u2122 (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that Russell Trenary has stepped down as the Company\u2019s President and Chief Executive Officer (CEO), effective immediately. Lawrence Kenyon, Executive Vice President, Chief Financial Officer and member of the board of directors, has been appointed Interim CEO.<\/p>\n<p align=\"justify\">\u201cOn behalf of our management team and board, I would like to thank Russ for his dedication and many contributions to the Company and wish him the best in his future endeavors,\u201d commented Randy Thurman, the Company\u2019s Executive Chairman. \u201cWe are pleased to have Larry lead Outlook Therapeutics during this transition period. We remain committed to our plans to resubmit the BLA for ONS-5010 in the first quarter of calendar 2025 and to begin sales of LYTENAVA\u2122 in Europe in the first half of calendar 2025.\u201d<\/p>\n<p align=\"justify\">Mr. Kenyon has served as the Company\u2019s Chief Financial Officer and Secretary since September 2015. He has been a member of Outlook Therapeutics\u2019 board of directors since August 2018 and also served as the Company\u2019s President and CEO from August 2018 to July 2021.<\/p>\n<p align=\"justify\">The Company has engaged an executive search firm to work with the board of directors to identify a permanent CEO.<\/p>\n<p align=\"justify\">\n        <strong>About Outlook Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010\/LYTENAVA\u2122 (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA\u2122 (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA\u2122 (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the first half of calendar 2025. In the United States, ONS-5010\/LYTENAVA\u2122 is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA to the FDA in the United States. If approved in the United States, ONS-5010\/LYTENAVA\u2122 would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements. All statements other than statements of historical facts are \u201cforward-looking statements,\u201d including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as \u201canticipate,\u201d \u201ccontinue,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cwill,\u201d or \u201cwould\u201d the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, plans for commercial launch of LYTENAVA\u2122 in the UK and EU and timing thereof, Outlook Therapeutics\u2019 commercialization strategy, the therapeutic potential of LYTENAVA\u2122 as a treatment of wet AMD, ONS-5010\u2019s potential as the first FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal indications, including wet AMD, in the United States, expectations concerning Outlook Therapeutics\u2019 ability to remediate or otherwise resolve deficiencies identified in the CRL issued by the FDA, including plans to resubmit the BLA for ONS-5010 and the timing thereof, expectations concerning decisions of regulatory bodies and the timing thereof, and other statements that are not historical fact. Although\u00a0Outlook Therapeutics\u00a0believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting\u00a0Outlook Therapeutics\u00a0and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, including the risk that the data from the NORSE EIGHT trial does not support the resubmission or subsequent filing by the FDA of the ONS-5010 BLA, the content and timing of decisions by regulatory bodies, the sufficiency of Outlook Therapeutics\u2019 resources, as well as those risks detailed in Outlook Therapeutics\u2019 filings with the\u00a0Securities and Exchange Commission\u00a0(the\u00a0SEC), including the Annual Report on Form 10-K for the fiscal year ended\u00a0September 30, 2023, filed with the\u00a0SEC\u00a0on\u00a0December 22, 2023, and future quarterly reports\u00a0Outlook Therapeutics\u00a0files with the\u00a0SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, high interest rates, inflation and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.\u00a0Outlook Therapeutics\u00a0does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.<\/p>\n<p>\n        <strong>Investor Inquiries:<\/strong><br \/>\n        <br \/> Jenene Thomas<br \/> Chief Executive Officer<br \/> JTC Team, LLC<br \/> T: 908.824.0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TucG3yl5rtOdfvBA0X8MtI5QGmZxnd4xDbx4dOaj0MB78omS_jHHW1PQVmGcj_rfH-6RRFtyGdWpBLOxUKs40g==\" rel=\"nofollow\" target=\"_blank\">OTLK@jtcir.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzU0NSM2NjIxMjU2IzIwMjg4MjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzM0NzFhODEtMzlmMy00ZTUwLWIxODAtMmYyZTA3ZWJjNjA1LTEwNDAzOTM=\/tiny\/Outlook-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA\u2122 (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that Russell Trenary has stepped down as the Company\u2019s President and Chief Executive Officer (CEO), effective immediately. Lawrence Kenyon, Executive Vice President, Chief Financial Officer and member of the board of directors, has been appointed Interim CEO. \u201cOn behalf of our management team and board, I would like to thank Russ for his dedication and many contributions to the Company and wish him the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Outlook Therapeutics\u00ae Announces Executive Leadership Transition&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-792171","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Outlook Therapeutics\u00ae Announces Executive Leadership Transition - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Outlook Therapeutics\u00ae Announces Executive Leadership Transition - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA\u2122 (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that Russell Trenary has stepped down as the Company\u2019s President and Chief Executive Officer (CEO), effective immediately. Lawrence Kenyon, Executive Vice President, Chief Financial Officer and member of the board of directors, has been appointed Interim CEO. \u201cOn behalf of our management team and board, I would like to thank Russ for his dedication and many contributions to the Company and wish him the &hellip; Continue reading &quot;Outlook Therapeutics\u00ae Announces Executive Leadership Transition&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-03T21:36:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzU0NSM2NjIxMjU2IzIwMjg4MjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-announces-executive-leadership-transition\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-announces-executive-leadership-transition\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Outlook Therapeutics\u00ae Announces Executive Leadership Transition\",\"datePublished\":\"2024-12-03T21:36:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-announces-executive-leadership-transition\\\/\"},\"wordCount\":886,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-announces-executive-leadership-transition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMzU0NSM2NjIxMjU2IzIwMjg4MjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-announces-executive-leadership-transition\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-announces-executive-leadership-transition\\\/\",\"name\":\"Outlook Therapeutics\u00ae Announces Executive Leadership Transition - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-announces-executive-leadership-transition\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-announces-executive-leadership-transition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMzU0NSM2NjIxMjU2IzIwMjg4MjI=\",\"datePublished\":\"2024-12-03T21:36:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-announces-executive-leadership-transition\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-announces-executive-leadership-transition\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-announces-executive-leadership-transition\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMzU0NSM2NjIxMjU2IzIwMjg4MjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMzU0NSM2NjIxMjU2IzIwMjg4MjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-announces-executive-leadership-transition\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Outlook Therapeutics\u00ae Announces Executive Leadership Transition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Outlook Therapeutics\u00ae Announces Executive Leadership Transition - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/","og_locale":"en_US","og_type":"article","og_title":"Outlook Therapeutics\u00ae Announces Executive Leadership Transition - Market Newsdesk","og_description":"ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA\u2122 (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that Russell Trenary has stepped down as the Company\u2019s President and Chief Executive Officer (CEO), effective immediately. Lawrence Kenyon, Executive Vice President, Chief Financial Officer and member of the board of directors, has been appointed Interim CEO. \u201cOn behalf of our management team and board, I would like to thank Russ for his dedication and many contributions to the Company and wish him the &hellip; Continue reading \"Outlook Therapeutics\u00ae Announces Executive Leadership Transition\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-03T21:36:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzU0NSM2NjIxMjU2IzIwMjg4MjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Outlook Therapeutics\u00ae Announces Executive Leadership Transition","datePublished":"2024-12-03T21:36:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/"},"wordCount":886,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzU0NSM2NjIxMjU2IzIwMjg4MjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/","name":"Outlook Therapeutics\u00ae Announces Executive Leadership Transition - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzU0NSM2NjIxMjU2IzIwMjg4MjI=","datePublished":"2024-12-03T21:36:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzU0NSM2NjIxMjU2IzIwMjg4MjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzU0NSM2NjIxMjU2IzIwMjg4MjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-announces-executive-leadership-transition\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Outlook Therapeutics\u00ae Announces Executive Leadership Transition"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/792171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=792171"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/792171\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=792171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=792171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=792171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}